EWTX
Edgewise Therapeutics Inc
NASDAQ: EWTX · HEALTHCARE · BIOTECHNOLOGY
$30.45
-1.74% today
Updated 2026-04-29
Market cap
$3.27B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.63
Dividend yield
—
52W range
$12 – $35
Volume
0.9M
Edgewise Therapeutics Inc (EWTX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | $123000.00 | $185000.00 | $272000.00 | $538000.00 | $1.73M | $2.29M | $2.27M |
| Gross profit | $-123000.00 | $-185000.00 | $-272000.00 | $-538000.00 | $-1.73M | $-2.29M | $-2.27M |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $8.62M | $14.80M | $32.19M | $16.61M | $90.91M | $126.97M | $151.39M |
| SG&A | $1.30M | $2.21M | $11.03M | $5.47M | $23.45M | $31.87M | $40.02M |
| Operating income | $-9.92M | $-17.19M | $-43.22M | $-22.08M | $-114.36M | $-158.83M | $-191.41M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | $-9.80M | $-17.01M | $-42.94M | $-21.54M | $-112.63M | $-156.54M | $-165.53M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-9.92M | $-17.19M | $-43.22M | $-22.08M | $-114.36M | $-158.83M | $-167.79M |
| Interest expense | $0.00 | $69000.00 | $272000.00 | $4.02M | — | — | — |
| Income tax | $-219000.00 | $-69000.00 | $-674000.00 | $-4.02M | — | $-1.00 | — |
| Effective tax rate | 2.3% | 0.4% | 1.6% | 20.7% | 0.0% | 0.0% | 0.0% |
| Net income | $-9.49M | $-17.05M | $-42.14M | $-15.40M | $-100.16M | $-133.81M | $-167.79M |
| Net income growth (YoY) | — | -79.8% | -147.1% | +63.5% | -550.5% | -33.6% | -25.4% |
| Profit margin | — | — | — | — | — | — | — |